Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-074968
Filing Date
2025-08-12
Accepted
2025-08-12 16:15:47
Documents
60
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0249801-10q_hoth.htm   iXBRL 10-Q 723681
2 CERTIFICATION ea024980101ex31-1_hoth.htm EX-31.1 11528
3 CERTIFICATION ea024980101ex31-2_hoth.htm EX-31.2 11536
4 CERTIFICATION ea024980101ex32-1_hoth.htm EX-32.1 3819
5 CERTIFICATION ea024980101ex32-2_hoth.htm EX-32.2 3864
  Complete submission text file 0001213900-25-074968.txt   5024805

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE hoth-20250630.xsd EX-101.SCH 47909
7 XBRL CALCULATION FILE hoth-20250630_cal.xml EX-101.CAL 27440
8 XBRL DEFINITION FILE hoth-20250630_def.xml EX-101.DEF 236349
9 XBRL LABEL FILE hoth-20250630_lab.xml EX-101.LAB 438839
10 XBRL PRESENTATION FILE hoth-20250630_pre.xml EX-101.PRE 254738
62 EXTRACTED XBRL INSTANCE DOCUMENT ea0249801-10q_hoth_htm.xml XML 583913
Mailing Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036
Business Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036 (646)756-2997
Hoth Therapeutics, Inc. (Filer) CIK: 0001711786 (see all company filings)

EIN.: 821553794 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38803 | Film No.: 251206903
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)